Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: macrogol 4000; hypromellose; colloidal anhydrous silica; magnesium stearate; propylene glycol; microcrystalline cellulose; lactose monohydrate; purified talc; titanium dioxide; croscarmellose sodium - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression, in adults, of chronic, recurrent urinary tract infection.

Malta - English - Medicines Authority

ecosse limited “mangion building”, new street off valletta road, luqa, lqa 6000, malta - metronidazole - film-coated tablet - metronidazole 400 mg - antibacterials for systemic use

Malta - English - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - metronidazole - film-coated tablet - metronidazole 400 mg - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note. specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - metronidazole 400mg - film coated tablet - 400 mg - active: metronidazole 400mg excipient: calcium hydrogen phosphate dihydrate macrogol 400 magnesium stearate maize starch pharmacoat povidone

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - metronidazole - film-coated tablet - 400 milligram(s) - metronidazole

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - metronidazole - oral tablet - 400mg

Israel - English - Ministry of Health

sanofi israel ltd - metronidazole - film coated tablets - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria, lambliasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: hypromellose; macrogol 400; magnesium stearate; maize starch; povidone; calcium hydrogen phosphate - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: hypromellose; magnesium stearate; purified talc; calcium hydrogen phosphate; macrogol 400; maize starch; povidone - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.